Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Cancer Cell International
Published in: Cancer Cell International 1/2015

Open Access 01-12-2015 | Primary research

The association between expressions of Ras and CD68 in the angiogenesis of breast cancers

Authors: Wei Li, Rong-Rui Liang, Chong Zhou, Meng-Yao Wu, Lian Lian, Gao-Feng Yuan, Ming-Yun Wang, Xin Xie, Liu-Mei Shou, Fei-Ran Gong, Kai Chen, Wei-Ming Duan, Min Tao

Published in: Cancer Cell International | Issue 1/2015

Login to get access

Abstract

Objective

Angiogenesis is a critical step of breast cancer metastasis. Oncogenic Ras promotes the remodeling of cancer microenviroment. Tumor-associated macrophages (TAMs) are a prominent inflammatory cell population emerging in the microenviroment and facilitating the angiogenesis and metastasis. In the present study, we tried to investigate the relationship between the expression of Ras and infiltration of TAM, both of which could further promote angiogenesis.

Methods

Expressions of Ras, CD68 and CD34 were assessed by immunohistochemistry. The infiltration of macrophages was evaluated by counting the number of CD68+ cells. Vessel endothelial cells were defined as CD34+ cells. Angiogenesis vascularity was defined by microvessel density (MVD) assay through counting the number of vessels per field counted in the area of highest vascular density. The Kaplan–Meier survival analysis was used to estimate the overall survival (OS). Macrophages were derived from monocytes in the presence of macrophage colony-stimulating-factor (MCSF). Breast cancer cells were treated with macrophage-conditioned medium (MCM) and tested the expressions of K-, H- and N-Ras by using realtime-PCR.

Results

Ras positive status was correlated with ER, PR and Her-2 positivity, larger tumour size and lymph node metastasis, as well as higher TNM stages. A higher number of CD68+ cells was correlated with larger tumour size, higher TNM stages and Her-2 positivity. Both Ras positivity and infiltration of CD68+ macrophages correlated with poor OS. The number of CD68+ cells was positively correlated with the expression of Ras. Treatment with MCM did not up-regulate but repressed the expression of Ras. Both up-regulation of Ras and infiltration of TAMs correlated with increased MVD.

Conclusion

Expression of Ras and infiltration of TAM were positively correlated, and both participated in angiogenesis. Elevated Ras could be responsible for the infiltration of TAM.
Literature
1.
Tao M, Ma D, Li Y, Zhou C, Zhang Y, Duan W, et al. Clinical significance of circulating tumor cells in breast cancer patients. Breast Cancer Res Treat. 2011;129(1):247–54.CrossRefPubMed
2.
Lian L, Li W, Li ZY, Mao YX, Zhang YT, Zhao YM, et al. Inhibition of MCF-7 breast cancer cell-induced platelet aggregation using a combination of antiplatelet drugs. Oncol Letters. 2013;5(2):675–80.
3.
Shou LM, Zhang QY, Li W, Xie X, Chen K, Lian L, et al. Cantharidin and norcantharidin inhibit the ability of MCF-7 cells to adhere to platelets via protein kinase C pathway-dependent downregulation of alpha2 integrin. Oncol Rep. 2013;30(3):1059–66.PubMedCentralPubMed
4.
Chen K, Shou LM, Lin F, Duan WM, Wu MY, Xie X, et al. Artesunate induces G2/M cell cycle arrest through autophagy induction in breast cancer cells. Anti-Cancer Drugs. 2014;25(6):652–62.PubMed
5.
Jimenez B, Volpert OV. Mechanistic insights on the inhibition of tumor angiogenesis. J Mol Med (Berl). 2001;78(12):663–72.CrossRef
6.
Bottini A, Berruti A, Bersiga A, Brizzi MP, Allevi G, Bolsi G, et al. Changes in microvessel density as assessed by CD34 antibodies after primary chemotherapy in human breast cancer. Clin Cancer Res Off J Am Assoc Cancer Res. 2002;8(6):1816–21.
7.
Fox SB, Harris AL. Histological quantitation of tumour angiogenesis. APMIS Acta Pathologica Microbiologica, et Immunologica Scandinavica. 2004;112(7–8):413–30.CrossRef
8.
Uzzan B, Nicolas P, Cucherat M, Perret GY. Microvessel density as a prognostic factor in women with breast cancer: a systematic review of the literature and meta-analysis. Cancer Res. 2004;64(9):2941–55.CrossRefPubMed
9.
Weidner N, Semple JP, Welch WR, Folkman J. Tumor angiogenesis and metastasis–correlation in invasive breast carcinoma. N Engl J Med. 1991;324(1):1–8.CrossRefPubMed
10.
Weidner N, Folkman J, Pozza F, Bevilacqua P, Allred EN, Moore DH, et al. Tumor angiogenesis: a new significant and independent prognostic indicator in early-stage breast carcinoma. J Natl Cancer Inst. 1992;84(24):1875–87.CrossRefPubMed
11.
12.
Coffelt SB, Hughes R, Lewis CE. Tumor-associated macrophages: effectors of angiogenesis and tumor progression. Biochim Biophys Acta. 2009;1796(1):11–8.PubMed
13.
14.
Downward J. Targeting RAS signalling pathways in cancer therapy. Nat Rev Cancer. 2003;3(1):11–22.CrossRefPubMed
15.
Ji H, Houghton AM, Mariani TJ, Perera S, Kim CB, Padera R, et al. K-ras activation generates an inflammatory response in lung tumors. Oncogene. 2006;25(14):2105–12.CrossRefPubMed
16.
Schmidt S, Gericke B, Fracasso G, Ramarli D, Colombatti M, Naim HY. Discriminatory role of detergent-resistant membranes in the dimerization and endocytosis of prostate-specific membrane antigen. PLoS One. 2013;8(6):e66193.CrossRefPubMedCentralPubMed
17.
Colombatti M, Grasso S, Porzia A, Fracasso G, Scupoli MT, Cingarlini S, et al. The prostate specific membrane antigen regulates the expression of IL-6 and CCL5 in prostate tumour cells by activating the MAPK pathways. PLoS One. 2009;4(2):e4608.CrossRefPubMedCentralPubMed
18.
Sunaga N, Imai H, Shimizu K, Shames DS, Kakegawa S, Girard L, et al. Oncogenic KRAS-induced interleukin-8 overexpression promotes cell growth and migration and contributes to aggressive phenotypes of non-small cell lung cancer. Int J Cancer J Int du Cancer. 2012;130(8):1733–44.CrossRef
19.
Sobin LH, Fleming ID. TNM classification of malignant tumors, fifth edition (1997). union internationale contre le cancer and the american joint committee on cancer. Cancer. 1997;80(9):1803–4.CrossRefPubMed
20.
Carlson RW, McCormick B. Update: NCCN breast cancer clinical practice guidelines. J National Comprehensive Cancer Network : JNCCN. 2005;3 Suppl 1:S7–11.
21.
Kim DW, Min HS, Lee KH, Kim YJ, Oh DY, Jeon YK, et al. High tumour islet macrophage infiltration correlates with improved patient survival but not with EGFR mutations, gene copy number or protein expression in resected non-small cell lung cancer. Br J Cancer. 2008;98(6):1118–24.CrossRefPubMedCentralPubMed
22.
Ancrile BB, O’Hayer KM, Counter CM. Oncogenic ras-induced expression of cytokines: a new target of anti-cancer therapeutics. Mol Interv. 2008;8(1):22–7.CrossRefPubMedCentralPubMed
23.
Ozer E, Sis B, Ozen E, Sakizli M, Canda T, Sarioglu S. BRCA1, C-erbB-2, and H-ras gene expressions in young women with breast cancer. An immunohistochemical study. Appl Immunohistochemistry Molecular Morphol AIMM/Off Publ Soc Appl Immunohistochemistry. 2000;8(1):12–8.CrossRef
24.
Mantovani A, Marchesi F, Porta C, Sica A, Allavena P. Inflammation and cancer: breast cancer as a prototype. Breast. 2007;16 Suppl 2:S27–33.CrossRefPubMed
25.
Viacava P, Naccarato AG, Bocci G, Fanelli G, Aretini P, Lonobile A, et al. Angiogenesis and VEGF expression in pre-invasive lesions of the human breast. J Pathol. 2004;204(2):140–6.CrossRefPubMed
26.
Cao Y, Paner GP, Kahn LB, Rajan PB. Noninvasive carcinoma of the breast: angiogenesis and cell proliferation. Archives Pathol Laboratory Med. 2004;128(8):893–6.
27.
Dhakal HP, Bassarova A, Naume B, Synnestvedt M, Borgen E, Kaaresen R, et al. Breast carcinoma vascularity: a comparison of manual microvessel count and Chalkley count. Histol Histopathol. 2009;24(8):1049–59.PubMed
28.
Tang Y, Kim M, Carrasco D, Kung AL, Chin L, Weissleder R. In vivo assessment of RAS-dependent maintenance of tumor angiogenesis by real-time magnetic resonance imaging. Cancer Res. 2005;65(18):8324–30.CrossRefPubMed
29.
Rak J, Mitsuhashi Y, Sheehan C, Tamir A, Viloria-Petit A, Filmus J, et al. Oncogenes and tumor angiogenesis: differential modes of vascular endothelial growth factor up-regulation in ras-transformed epithelial cells and fibroblasts. Cancer Res. 2000;60(2):490–8.PubMed
Metadata
Title
The association between expressions of Ras and CD68 in the angiogenesis of breast cancers
Authors
Wei Li
Rong-Rui Liang
Chong Zhou
Meng-Yao Wu
Lian Lian
Gao-Feng Yuan
Ming-Yun Wang
Xin Xie
Liu-Mei Shou
Fei-Ran Gong
Kai Chen
Wei-Ming Duan
Min Tao
Publication date
01-12-2015
Publisher
BioMed Central
Published in
Cancer Cell International / Issue 1/2015
Electronic ISSN: 1475-2867
DOI
https://doi.org/10.1186/s12935-015-0169-1

Other articles of this Issue 1/2015

Cancer Cell International 1/2015 Go to the issue

Primary research

Stromal-epithelial responses to fractionated radiotherapy in a breast cancer microenvironment

Primary research

STAT1 inhibits human hepatocellular carcinoma cell growth through induction of p53 and Fbxw7

Primary research

Antihelminthic benzimidazoles potentiate navitoclax (ABT-263) activity by inducing Noxa-dependent apoptosis in non-small cell lung cancer (NSCLC) cell lines

Primary research

Kinetic characterization of lactate dehydrogenase in normal and malignant human breast tissues

Primary research

High-grade serous ovarian cancer cell lines exhibit heterogeneous responses to growth factor stimulation

Review

Overview on the complexity of androgen receptor-targeted therapy for prostate cancer
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits